Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1311654 | 0.98 | FFAR1 (0.38) | FFAR1KEAP1P4HTMNPSR1TBXAS1 | |
| Hydrochloric Acid SCHEMBL6625511 | 0.98 | FFAR1 (0.38) | FFAR1KEAP1P4HTMNPSR1TBXAS1 | |
| SCHEMBL18906027 | 0.89 | SMN1; SMN2 (0.41) | TBXAS1 | |
| SCHEMBL291231 | 0.87 | TBXAS1 (0.46) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL11161336 | 0.87 | TBXAS1 (0.41) | TBXAS1 | |
| Histamine SCHEMBL5321413 | 0.85 | LMNA (0.33) | P4HTMNPSR1TBXAS1 | |
| SCHEMBL2896033 | 0.85 | TBXAS1 (0.49) | TBXAS1 | |
| SCHEMBL26589771 | 0.85 | TBXAS1 (0.49) | TBXAS1 | |
| Histamine SCHEMBL1680140 | 0.85 | LMNA (0.33) | P4HTMNPSR1TBXAS1 | |
| SCHEMBL6443420 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689898-B1 | LONG-ACTING CONJUGATE OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) DERIVATIVE | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-29 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| US-20250311759-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-09 | — | — | US | claimed |
| WO-2025069009-A1 | ROCK2 INHIBITORS IN THE TREATMENT OF OBESITY | GRAVITON BIOSCIENCE BV (NL) | 2025-04-03 | — | — | WO | claimed |
| CN-119325387-A | Combination therapy of GLP-2 with insulinotropic peptide, TNFa inhibitor or both for preventing or treating intestinal diseases | 韩美药品株式会社 | 2025-01-17 | — | — | CN | claimed |
| WO-2024245421-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| CN-118401257-A | Methods for producing antibody peptide conjugates | 美国安进公司 | 2024-07-26 | — | — | CN | claimed |
| CN-110831969-B | Methods of treating or ameliorating metabolic disorders using a combination of a Gastric Inhibitory Peptide Receptor (GIPR) binding protein and a GLP-1 agonist | 安进公司 | 2024-06-21 | — | — | CN | claimed |
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| CN-118079021-A | Treatment or amelioration of metabolic disorders using GLP-1 receptor agonists coupled to Gastric Inhibitory Peptide Receptor (GIPR) antagonists | 美国安进公司 | 2024-05-28 | — | — | CN | claimed |
| EP-3118211-A1 | AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2017-01-18 | — | — | EP | claimed |
| US-20090011124-A1 | Complexes of zinc with substituted amidines and guanidines and aliphatic carboxylates, e.g., Zn(1-methylimidazole)2(acetate)2 and Zn(1-methylimidazole)2(2-ethylhexanoate)2; useful as catalysts for deblocking blocked isocyanates and in the production of urethanes and polyurethanes | HSIEH BING | 2009-01-08 | — | — | US | claimed |
| EP-1778778-A2 | ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS | King Industries, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060247341-A1 | Complexes of zinc with substituted amidines and guanidines and aliphatic carboxylates, e.g., Zn(1-methylimidazole)2(acetate)2 and Zn(tetramethylguanidine)2(formate)2; useful as catalysts for deblocking blocked isocyanates and in the production of urethanes and polyurethanes | KING INDUSTRIES, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2006022899-A2 | ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS | KING INDUSTRIES, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060036007-A1 | Organometallic compositions and coating compositions | KING INDUSTRIES, INC. (US) | 2006-02-16 | — | — | US | claimed |
| CN-1338456-A | Benzodiazepine compound containing imidazole propionamido and preparation method and application thereof | INST OF MEDICAL MATERIALS CHIN (CN) | 2002-03-06 | — | — | CN | claimed |
| EP-0597088-B1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INST NAT SANTE RECH MED (FR) | 2000-12-06 | — | — | EP | claimed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| CN-1112125-A | Acyloxyhexanoic acid derivatives | CIBA GEIGY AG (CH) | 1995-11-22 | — | — | CN | claimed |